The aim of this work was to unveil the metabolic characteristics of acquired resistance to BRAF inhibitors in BRAF-mutant melanoma cells and identify novel pathways that could provide targeted combinatorial strategies with BRAF inhibitors. This evidence concerns the gene BRAF and melanoma.